All entries for: Gastrointestinal

May 22, 2026

AbbVie

Layoffs

North Chicago, IL

10,000+ employees

AbbVie’s operations in Irvine, California, will be 85 employees leaner after July 20, with layoffs projected to take place on that date, according to a Worker Adjustment and Retraining Notification (WARN) Act alert.

The pharma has over 40 open posts available in California, including data science and biologics product development listings. A recent BioSpace report found that AbbVie CEO Robert Michael saw a 76% pay bump, with his total compensation package reaching $32.5 million last year as compared to $18.5 million in 2024.

As per BioSpace’s tally, this is the first time AbbVie has announced layoffs this year.

Disease Area: Dermatology, Gastrointestinal, Multiple, Neurological Diseases, Oncology

Drug Type: Biologic, Small Molecule

Source

May 12, 2026

CalciMedica, Inc.

Neutral Outlook

La Jolla, California

1-50 employees

While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain whether it will affect our patent strategy in the long run.

Disease Area: Cardiology, Gastrointestinal, Immune Diseases, Respiratory Diseases

Drug Type: Small Molecule

Source

April 30, 2026

Ardelyx

Neutral Outlook

Waltham, MA

201-500 employees

While the impact of the IRA on us and the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.

Disease Area: Cardiology, Chronic Disease, Gastrointestinal, Metabolic Diseases, Multiple

Drug Type: Small Molecule

Source

April 23, 2026

Agomab Therapeutics NV

Neutral Outlook

Antwerpen, Belgium

51-200 employees

Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the pharmaceutical industry.

Disease Area: Gastrointestinal, Respiratory Diseases

Drug Type: Small Molecule

Source

March 20, 2026

Palisade Bio, Inc

Negative Outlook

Denver, CO

1-50 employees

The Inflation Reduction Act of 2022 (“IRA”) also makes several changes to the Medicare Part D benefit, including an updated limit on annual out-of-pocket costs, a change in manufacturer liability under the program which could negatively affect our business and financial condition, and sunset of the existing coverage gap and coverage gap discount program,.

Disease Area: Gastrointestinal

Drug Type: Small Molecule

Source

March 18, 2026

Processa Pharmaceuticals

Neutral Outlook

Vero Beach, FL

1-50 employees

Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (“IRA”) into law, which among other things, extended enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025.

Disease Area: Gastrointestinal, Oncology

Drug Type: Small Molecule

Source

March 11, 2026

Sagimet Biosciences Inc.

Neutral Outlook

San Mateo, CA

1-50 employees

The effects of the IRA on our business and the healthcare industry in general is not yet known.

Disease Area: Dermatology, Gastrointestinal, Metabolic Diseases, Oncology

Drug Type: Small Molecule

Source

March 10, 2026

Esperion Therapeutics, Inc.

Neutral Outlook

Ann Arbor, MI

201-500 employees

Although the effects of the IRA on our business and the healthcare industry in general are not yet known, we are taking into consideration the potential impact of the IRA on our development and commercialization activities.

Disease Area: Cardiology, Gastrointestinal, Metabolic Diseases

Drug Type: Small Molecule

Source

March 5, 2026

GSK plc

Negative Outlook

London, England

10,000+ employees

In ovarian cancer, Zejula saw a decrease in sales, driven by ongoing volume reductions, including impacts of an FDA labelling update restricting use to certain patient populations, and the impacts of IRA Medicare Part D redesign in the US

Disease Area: Antiviral, Chronic Disease, Gastrointestinal, Hematology, Immune Diseases, Infectious Diseases, Metabolic Diseases, Oncology, Respiratory Diseases

Drug Type: Biologic, Small Molecule

Source

March 5, 2026

Altimmune, Inc

Neutral Outlook

Gaithersburg, MD

1-50 employees

The effect of IRA on our business and the healthcare industry in general is not yet known.

Disease Area: Chronic Disease, Gastrointestinal, Metabolic Diseases

Drug Type: Biologic, Small Molecule

Source